Ira Braunschweig, MD, discusses mitigating the toxicities that are associated with CAR T-cell therapy in lymphoma.
Ira Braunschweig, MD
Advertisement
Articles by Ira Braunschweig, MD
Ira Braunschweig, MD, discusses factors to consider when selecting between autologous stem cell transplant, allogeneic stem cell transplant, and CAR T-cell therapy in diffuse large B-cell lymphoma.
Advertisement
Latest Updated Articles
Dr. Braunschweig on Selecting Between Transplant and CAR T-Cell Therapy in DLBCLPublished: November 4th 2020 | Updated:
Dr. Braunschweig on Mitigating the Toxicities of CAR T-Cell Therapy in LymphomaPublished: November 5th 2020 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
FasTCAR Manufactured BCMAxCD19 CAR T-cell Therapy Shows Promise for Multiple Myeloma
2
Autologous Stem Cell Therapy for Alzheimer Disease Advances to Phase 2 After Positive Early Findings
3
FDA Approves BMS’s Liso-Cel for R/R Marginal Zone Lymphoma
4
ImmunoLogic, Episode 7: "Turbocharging CAR T-Cells: The IL-9 Orthogonal Signal" With Anusha Kalbasi, MD
5
